Vol. 45 | No. 1 | January-June 2017Back

Open Access

Sulodexide as an Adjunct for the Management of Venous Ulcers: A Meta-analysis

Joseph Marc Seguban, Michelle Andrea Uy-Reyes, Allan Lim, Elaine Alajar, Noemi Pestaño, Felix Eduardo Punzalan, Bernadette Tumanan-Mendoza
Jun 2017 DOI 10.69944/pjc.71188b6946

More Info

Joseph Marc Seguban, MD; Michelle Andrea Uy-Reyes, MD; Allan Lim, MD; Elaine Alajar, MD;  Noemi Pestaño, MD; Felix Eduardo Punzalan, MD; Bernadette Tumanan-Mendoza, MD

Section of Cardiology, Department of Internal Medicine, Manila Doctors Hospital

References
  1. Royal College of Nursing Institute. The Management of Patients with  Venous Leg Ulcers: Recommendations for Assessment, Compression  Therapy, Cleansing, Debridement, Dressing, Contact Sensitivity,  Training/Education and Quality Assurance. London: Royal College  of Nursing, 1998. 
  2. Jank nas V, Rimdeika R, Jasenas M, Samsanavicius D. Changes in  patient’s quality of life comparing conservative and surgical treatment  of venous leg ulcers. Medicina (Kaunas). 2004;40(8):731–9. 
  3. Andreozzi G. Sulodexide in the treatment of chronic venous disease.  Am J Cardiovasc Drugs. 2012;12(2):73–81.  
  4. O’Meara S, Cullum N, Nelson EA, Dumville JC. Compression  for venous leg ulcers. Cochrane Database of Systematic Reviews  2012;(11). Art. No.: CD000265.  
  5. Callam MJ, et al. Lothian and Forth Valley leg ulcer healing trial, part  1: elastic versus non-elastic bandaging in the treatment of chronic leg  ulceration. Phlebology. 1992;7(4):136-41.  
  6. Moffatt CJ, Franks PJ, Doherty DC, Martin R, Blewett R, Ross  F. Prevalence of leg ulceration in a London population. QJM.  2004;97(7):431–7. 
  7. Takahashi PY, Chandra A, Cha SS, Crane SJ. A predictive model  for venous ulceration in older adults: results of a retrospective cohort  study. Ostomy Wound Manage. 2010;56(4):60–6. 
  8. Kurz N, Kahn SR, Abenhaim L. VEINES Task Force Report:  The management of chronic venous disorders of the leg (CVDL):  an evidence-based report of an international task force. McGill  University. Sir Mortimer B. Davis-Jewish General Hospital. Summary  reports in: Angiology. 1997;48(1):59-66. 
  9. Heit JA. Venous thromboembolism epidemiology: implications for  prevention and management. Semin Thromb Hemost. 2002;28  (suppl 2):3–13. 
  10. Apollonio A, Antignani PL, Di Salvo M, Failla G, Guarnera G, Mosti  G, et al. A large Italian observational multicentre study on vascular  ulcers of the lower limbs (Studio Ulcere Vascolari). Int Wound J.  2014;13(1):27–34. 
  11. Abbade LP, Lastória S. Venous ulcer: epidemiology, physiopathology,  diagnosis and treatment. Int J Dermatol. 2005;44(6):449–56.
  12. Cosmi B, Cini M, Legnani C, Pancani C, Calanni F, Coccheri S.  Additive thrombin inhibition by fast moving heparin and dermatan  sulfate explains the anticoagulant effect of sulodexide, a natural  mixture of glycosaminoglycans. Thromb Res. 2003;109(5–6): 333–9. 
  13. Nicolaides AN. Chronic venous disease and the leukocyte endothelium interaction: from symptoms to ulceration. Angiology.  2005;56(suppl 1):S11–9.  
  14. Ofosu FA. Pharmacological actions of sulodexide. Semin Thromb  Hemost. 1998;24(2):127–38. Review. 
  15. Harenberg J. Review of pharmacodynamics, pharmacokinetics, and  thera- peuticproperties of sulodexide. Med Res Rev. 1998;18(1):1–20. 
  16. Ciszewicz M, Polubinska A, Antoniewicz A, Suminska-Jasinska  K, Breborowicz A. Sulodexide suppresses inflammation in human  endothelial cells and prevents glucose cytotoxicity. Transl Res.  2009;153(3):118–23.  
  17. Lauver AD, Lucchesi BR. Sulodexide: a renewed interest in this  glycosaminoglycan. Cardiovasc Drug Rev. 2006;24(3–4):214–26.  Review.  
  18. Nelson EA. Venous leg ulcers. BMJ Clin Evid. 2011;2011.pii:1902.  Review. 
  19. Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL,  Gloviczki ML, et al. The care of patients with varicose veins and  associated chronic venous diseases: clinical practice guidelines of the  Society for Vascular Surgery and the American Venous Forum. J Vasc  Surg. 2011;53(5 Suppl):2S-48S. 
  20. O’Donnell TF Jr, Passman MA, Marston WA, Ennis WJ, Dalsing M,  Kistner RL, et al. Management of venous leg ulcers: clinical practice  guidelines of the Society for Vascular Surgery and the American  Venous Forum. J Vasc Surg. 2014;60(2 Suppl):3S–59S. 
  21. Varatharajan L, Thapar A, Lane T, Munster AB, Davies AH.  Pharmacological adjuncts for chronic venous ulcer healing: a  systematic review. Phlebology. 2016;31(5):356–65. 
  22. Scondotto G, Aloisi D, Ferrari P, Martini L. Treatment of venous leg  ulcers with sulodexide. Angiology. 1999;50(11):883–9.
  23. Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni  V; Venous arm of the SUAVIS (Sulodexide Arterial Venous Italian  Study) Group. Randomised, double blind, multicentre, placebo  controlled study of sulodexide in the treatment of venous leg ulcers.  Thromb Haemost. 2002;87(6):947–52. 
  24. Kucharzewski M, Franek A, Koziolek H. Treatment of venous leg  ulcers with sulodexide. Phlebologie. 2003;32(5):115-20.
  25. Falanga V, Saap LJ, Ozonoff A. Wound bed score and its correlation  with healing of chronic wounds. Dermatol Ther. 2006;19(6):383–90. 
  26. Kurz X, Kahn SR, Abenhaim L, Clement D. Chronic venous disorders  of the leg: Epidemiology, outcomes, diagnosis and management:  Summary of an evidence-based report on the VEINES task  force. International Angiology. 1999 Jun 1;18(2):83. Int Angiol.  1999;18(2):83–102.  
  27. Coccheri S, Mannello F. Development and use of sulodexide in  vascular diseases: implications for treatment. Drug Des Devel Ther.  2013 Dec 24;8:49–65.  
  28. Kucharzewski M, Franek A, Koziolek H. Treatment of venous leg  ulcers with sulodexide. Phlebologie. 2003;32(5):115–20.
  29. Mannello F, Medda V, Ligi D, Raffetto JD. Glycosaminoglycan  sulodexide inhibition of MMP-9 gelatinase secretion and activity:  Possible pharmacological role against collagen degradation in vascular  chronic diseases. Curr Vasc Pharmacol. 2013;11(3):354–65.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.